QQ客服 官方微博 反馈留言

	Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
	Song Yuqin; Gao Quanli; Zhang Huilai; Fan Lei; Zhou Jianfeng; Zou Dehui; Li Wei; Yang Haiyan; Liu Ting; Wang Quanshun
	2019
ISSN号	1476-5551
DOI	10.1038/s41375-019-0545-2
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6335553
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Song Yuqin,Gao Quanli,Zhang Huilai,et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study[J],2019.
APA	Song Yuqin.,Gao Quanli.,Zhang Huilai.,Fan Lei.,Zhou Jianfeng.,...&Zhu Jun.(2019).Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study..
MLA	Song Yuqin,et al."Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study".(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。